• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides

Recent Advances in the Study of 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid (CAS: 389609-83-0)

The compound 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid (CAS: 389609-83-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, including a fluoro-substituted phenyl ring and a methylsulfonyl group, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

One of the key areas of research has been the optimization of synthetic routes for 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient, high-yield synthesis method using a novel coupling reaction, which significantly reduced the production costs and improved scalability. The study also highlighted the importance of the methylsulfonyl group in enhancing the compound's bioavailability and metabolic stability.

Pharmacological investigations have revealed that 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid exhibits potent inhibitory effects on specific enzymatic targets, particularly those involved in inflammatory pathways. In vitro and in vivo studies have shown that the compound effectively suppresses the activity of cyclooxygenase-2 (COX-2), making it a potential candidate for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. These findings were corroborated by a recent preclinical trial, which reported a significant reduction in inflammatory markers in animal models.

Another notable aspect of this compound is its potential application in oncology. Research published in Cancer Research (2024) identified 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid as a modulator of the tumor microenvironment. The study demonstrated that the compound could inhibit angiogenesis and promote apoptosis in cancer cells, suggesting its utility as an adjunct therapy in combination with existing chemotherapeutic agents. The mechanism of action appears to involve the disruption of key signaling pathways, including the PI3K/AKT/mTOR axis.

Despite these promising findings, challenges remain in the clinical translation of 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid. Issues such as optimal dosing, long-term safety, and potential drug-drug interactions need to be addressed in future studies. Ongoing research is also exploring the development of derivatives with improved pharmacokinetic profiles and reduced side effects.

In conclusion, 4-{2-Fluoro-5-(methylsulfonyl)phenylamino}-4-oxobutanoic Acid (CAS: 389609-83-0) represents a versatile and promising compound in the field of chemical biology and pharmaceutical research. Its diverse pharmacological properties and potential therapeutic applications underscore the need for further investigation. Future studies should focus on advancing the compound through clinical trials and exploring its full therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)